BioArctic AB (publ) (BRCTF) Comparison with companies in other sectors?

BioArctic AB (publ) has a share price of 88.53M. You can analyze BioArctic AB (publ) (BRCTF) competitors across different market sectors through stock heatmaps.

What are BRCTF's NET and operating margins?

BioArctic AB (publ) (BRCTF) operating margin is around 0.61, and net profit margin is approximately 0.59 as of the latest reports.

In what way does BRCTF's earnings per share (EPS) trend reflect its financial momentum?

BioArctic AB (publ) (BRCTF) EPS is 1.07 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for BioArctic AB (publ) is 18.07, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for BioArctic AB (publ)?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for BioArctic AB (publ) like P/E which is 18.05, P/B which is 8.42, and PEG which is 0.003. Compare them with sector averages to evaluate if the stock is priced fairly.

BioArctic AB (publ)

BRCTF•PNK

Healthcare

Biotechnology

$19.34

$0.00(0.00%)

Fundamental Analysis of BioArctic AB (publ) (BRCTF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$1.07

P/E Ratio

18.07

ROE

0.77%

Net Margin

0.59%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.71B

Shares OutstandingTotal number of shares issued

$88.53M

Book Value/ShareNet worth per share

$21.86

Revenue/ShareAnnual revenue per share

$17.15

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.07

Net MarginNet income as percentage of revenue

59.44%

Operating MarginOperating income as percentage of revenue

60.62%

ROEReturn on shareholders' equity

77.14%

ROAReturn on total assets

42.48%

ROCEReturn on capital employed

46.65%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-2.15

Cash/ShareCash and equivalents per share

$8.91

FCF YieldFree cash flow as percentage of market cap

-1.17%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for BRCTFFinancial Ratios Analysis details for BRCTF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BRCTFSector Benchmarking details for BRCTF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for BioArctic AB (publ) Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of BioArctic AB (publ). Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account BioArctic AB (publ)'s unique business strengths and challenges.

Key Financial Metrics for BioArctic AB (publ)

For BioArctic AB (publ), essential financial indicators include EPS 1.07, PE 18.07, and ROE 0.77. These key ratios reveal insights into BioArctic AB (publ)'s profitability, valuation, and operational health. Understanding these metrics enables you to compare BioArctic AB (publ) with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of BioArctic AB (publ)

Metrics like Net Margin 59.44% and ROA 42.48% shed light on how well BioArctic AB (publ) is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether BioArctic AB (publ) can sustain its operations and continue growing in the future.

Valuation and Market Position of BioArctic AB (publ)

Using ratios such as P/B Ratio 8.42 and PEG Ratio 0.003, investors can assess whether BioArctic AB (publ) is appropriately valued based on its financials and growth potential. These figures, combined with BioArctic AB (publ)'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for BioArctic AB (publ)

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow $-2.15, provide a snapshot of BioArctic AB (publ)'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like BioArctic AB (publ), is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for BioArctic AB (publ)

Investing in BioArctic AB (publ) based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at BioArctic AB (publ) focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;